drugset / Trial / NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Timeline
- Start
- 2024-03-20
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GFH009 | Unknown | 60 mg | Intravenous |
| Subject | GFH009 | Unknown | 75 mg | Intravenous |
| Subject | GFH009 | Unknown | 100 mg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |